Demyelinating Diseases clinical trials

Explore recruiting demyelinating diseases clinical trials.

Recruiting demyelinating diseases studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Demyelinating Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

Germany, Austria

Phase II and Phase III (Integrated) EU CTIS Study details

Demyelinating Diseases trials by city

Demyelinating Diseases clinical trials

Recruiting demyelinating diseases studies right now

Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction

Cognitive-motor Telerehabilitation in MS

Blood Flow Restriction And Veterans With MS

High-throughput Omic Technology for Identification of Biomarkers of Relapsing Acute Disseminated Encephalomyelitis in Immune Cell Network

Motor Imagery and Action Observation for Gait Function in MS

Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)

High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Deciphering Preserved Autonomic Function After Multiple Sclerosis

Investigating Visuo-spatial Abilities and Psychological Effects in West Nile and Multiple Sclerosis Patients with a Focus on a Possible Rehabilitation Protocol

Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Also recruiting in Europe

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

Demyelinating Diseases trials by city

Other conditions